Page last updated: 2024-11-09

wiskostatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

wiskostatin: induces folding of N-WASP's GTPase-binding domain into its autoinhibited conformation; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

wiskostatin : A racemate comprising equimolar amounts of (R)- and (S)-wiskostatin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-(3,6-dibromocarbazol-9-yl)-3-(dimethylamino)propan-2-ol : A member of the class of carbazoles that is 1-(carbazol-9-yl)-3-(dimethylamino)propan-2-ol bearing two additional bromo substituents at positions 3 and 6 on the carbazole ring system. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2775510
CHEMBL ID1476463
CHEBI ID78012
SCHEMBL ID5800361
MeSH IDM0472589

Synonyms (58)

Synonym
9h-carbazole-9-ethanol, 3,6-dibromo-alpha-dimethylamino)methyl)
BRD-A18579359-001-03-1
1-(3,6-dibromocarbazol-9-yl)-3-(dimethylamino)propan-2-ol
QTL1_000090
IDI1_002235
BSPBIO_001280
BIO2_000480
BIO2_000960
CBDIVE_008357
NCGC00179231-01
BCBCMAP01_000077
SMP2_000156
OPREA1_105682
NCGC00163493-01
wiskostatin
KBIO3_001099
KBIO3_001100
KBIOSS_000620
KBIO2_000620
KBIOGR_000620
KBIO2_003188
KBIO2_005756
MAYBRIDGE1_002006
OPREA1_198540
HMS1990P21
HMS547D04
HMS1792P21
HMS1362P21
AKOS000630481
NCGC00163493-02
STK926891
1-(3,6-dibromo-9h-carbazol-9-yl)-3-(dimethylamino)propan-2-ol
253449-04-6
A817807
1-(3,6-dibromo-9-carbazolyl)-3-(dimethylamino)-2-propanol
1-[3,6-bis(bromanyl)carbazol-9-yl]-3-(dimethylamino)propan-2-ol
FT-0605599
AKOS016316422
c17h18br2n2o
CHEMBL1476463
CCG-222560
T-126
SCHEMBL5800361
CHEBI:78012 ,
J-503093
3,6-dibromo-?-[(dimethylamino)methyl]-9h-cabazole-9-ethanol
3,6-dibromo-alpha-[(dimethylamino)methyl ]-9h-cabazole-9-ethanol
HB0658
HMS3403P21
mfcd00218393
Z56770616
DTXSID80893518
Q27147585
EN300-311958
AS-75867
CS-0011991
HY-12534
E98646

Research Excerpts

Overview

Wiskostatin is a chemical inhibitor that selectively inhibits neuronal WASP (N-WASP)-mediated actin polymerization in vitro.

ExcerptReferenceRelevance
"Wiskostatin is a recently described chemical inhibitor that selectively inhibits neuronal WASP (N-WASP)-mediated actin polymerization in vitro."( N-WASP inhibitor wiskostatin nonselectively perturbs membrane transport by decreasing cellular ATP levels.
Guerriero, CJ; Weisz, OA, 2007
)
1.4

Treatment

ExcerptReferenceRelevance
"The Wiskostatin treated TM cells demonstrated extensive vacuoles in their cytosol, and both actin stress fibers and focal adhesions were decreased in a reversible manner."( Effects of chemical inhibition of N-WASP, a critical regulator of actin polymerization on aqueous humor outflow through the conventional pathway.
Epstein, DL; Inoue, T; Pattabiraman, PP; Vasantha Rao, P, 2010
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
carbazoles
organobromine compoundA compound containing at least one carbon-bromine bond.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency25.11890.180013.557439.8107AID1468
regulator of G-protein signaling 4Homo sapiens (human)Potency0.67020.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency35.48130.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency14.12540.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency31.62280.354828.065989.1251AID504847
survival motor neuron protein isoform dHomo sapiens (human)Potency5.01190.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1631708Antimalarial activity against Plasmodium falciparum NF54 infected in human erythrocytes assessed as [3H]-hypoxanthine incorporation by scintillation counting analysis2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles.
AID1631709Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles.
AID1631710Binding affinity to recombinant Plasmodium falciparum Hsp90 expressed in Escherichia coli BL21(DE3) pLysS assessed as thermophoresis shift at 50 uM by microscale thermophoresis assay2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles.
AID1172954Antibacterial activity against Pseudomonas aeruginosa after 24 hrs by two-fold broth microdilution method2014Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23
Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (38.71)29.6817
2010's17 (54.84)24.3611
2020's2 (6.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.68 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]